Introduction
This product is SinaDoxosome containing liposomal hydrochloride doxorubicin. Its formulation is in a way that inserts doxorubicin into the nanoliposome carriers and increases permeability and retention of the drug in the tumor tissue. This lipid carrier decreases the side effects of doxorubicin due to the small amount of leakage. In this way cardiac toxicity of the drug that is the most dangerous side effect is significantly reduced. SinaDoxosome is used in the treatment of various cancers and because of the high efficiency of its liposomal nature, it has significant effect on metastatic cancers including metastatic breast, ovarian cancers as well as multiple myeloma and AIDS-related Kaposi’s sarcoma.
Reviews
There are no reviews yet.